XML 41 R29.htm IDEA: XBRL DOCUMENT

Research, Collaboration and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2025

License Agreements Research Collaborations And Development Agreements [Abstract]

Schedule of Revenue Recognized from Strategic Partnerships

Revenue recognized from the Company’s strategic partnerships. which includes amounts from Jazz Pharmaceuticals Ireland Limited or Jazz Pharmaceuticals, Inc. (subsidiaries of Jazz Pharmaceuticals plc, collectively referred to as “Jazz”) is summarized as follows:


	Three Months Ended March 31,
	2025		2024
Jazz:
Development support payments	$	4,493	$	2,066
Drug supply for ongoing studies	2,957		6,218
Other drug supply	2,150		1,578
Royalties	202		—

BeiGene, Ltd. (“BeiGene”):
Drug supply	208		—

GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”):
Milestone revenue	14,000		—

Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”):
Milestone revenue	3,100		—

Research support and other payments from other partners	—		168
	$	27,110	$	10,030